Notizie e Video - APTOSE BIOSCIENCES INC. - Pagina 2

Attualmente stai visualizzando tutte le notizie di borsa dello strumento finanziario APTOSE BIOSCIENCES INC. in tutti i mercati in tutte le lingue.

> Notizie GlobeNewsWire ha pubblicato una nuova notizia.

Aptose Biosciences Reports Financial Results for the Third Quarter Ended September 30, 2016 • • GlobeNewsWire • Azioni

SAN DIEGO and TORONTO, Nov. 14, 2016 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced unaudited financial results for the three months ended September 30, 2016 and reported on corporate developments. Unless specified otherwise, all amounts are in Canadian dollars. Net loss for the three months ended September 30, 2016 was $4.0 million...

Grazie Grafico

> Notizie GlobeNewsWire ha pubblicato una nuova notizia.

Aptose To Release Third Quarter Ended September 30, 2016 Financial Results and Hold Conference Call on November 15, 2016 • • GlobeNewsWire • Azioni

SAN DIEGO and TORONTO, Nov. 10, 2016 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Aptose) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, will release its financial results for the quarter ended September 30, 2016, on Monday, November 14, 2016 after the close of the market. The company intends to host a conference call the following morning on Tuesday, November 15, 2016 at 8:30 a.m. ET to...

Grazie Grafico

> Notizie GlobeNewsWire ha pubblicato una nuova notizia.

Aptose to Present New APTO-253 Data at the 2016 ASH Annual Meeting • • GlobeNewsWire • Azioni

SAN DIEGO and TORONTO, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced that new preclinical data for its lead investigational anticancer therapeutic APTO-253 will be presented at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 3-6, 2016, in San Diego, CA. Poster...

Grazie Grafico

> Notizie GlobeNewsWire ha pubblicato una nuova notizia.

Aptose Provides Update on FDA Clinical Hold of APTO-253 • • GlobeNewsWire • Azioni

SAN DIEGO and TORONTO, Oct. 13, 2016 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced that it received a response from the U.S. Food and Drug Administration (FDA) regarding the clinical hold of Aptose’s Phase 1b clinical trial of APTO-253 in patients with hematologic cancers requesting additional information and informing Aptose...

Grazie Grafico